梁永｜清华大学｜学者主页

2026

Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance

Zuming Yang, Shuaishuai Cao, Jia-En Zhang, Xiao-Hua Nie, Zhi-Min Wang, Shao-Jun Yang, Jingshu Wang, Xin Sun, Xueli Kuang, Hui-Ming Huang, Zifan Wei, Pengfei Duan, Mingwang Tang, Li-Yu Zhang, Zhenhua Ren, Xun Lan, Yangbo Fu, Li-Guo Zhang, Xuyuan Zhang, Yong Liang

Signal Transduction and Targeted Therapy

精选作品

期刊论文

Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice

Anti–PD-L1–IFN-α–adjuvanted HBsAg vaccine overcomes HBV immune tolerance through targeting both DCs and macrophages

Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8+ T-cell proliferation

Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control.

Engineering cytokines for tumor-targeting and selective T cell activation.

Eliciting antitumor immunity via therapeutic cancer vaccines

Concurrent intratumoural Treg cell depletion and CD8+ T cell expansion via a cleavable anti-4-1BB–interleukin-15 fusion protein

Lymphotoxin-β promotes breast cancer bone metastasis colonization and osteolytic outgrowth

Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy

LIGHTing CAR T in the tumor microenvironment.

Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity

An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance

Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity

Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity

Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.

DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity

Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance

CTLA-4 limits anti-CD20-mediated tumor regression

STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy.

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

LIGHTing tumor up for checkpoint blockade

研究方向